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spp., were determined by the NCCLS broth microdilution method 
for conidium-forming filamentous fungi (M38-P document): stan- 
dard RPMI-1640 broth, G (Aspegillus spp.) and NG (Aspergillus spp. 
and emerging molds) conidial suspensions (-lo4 CFU/mL), and 48 
h of incubation at 35OC. MICs corresponded to approximately 50% 
or more (azoles) and complete growth inhibition (A). 
Results: Overall, MlCs of the five agents for the 55 Aspergillus 
spp, were the same or within 2 dilutions with NG and G inocula. 
The activities of the three new azoles were comparable (0.03-2 
pg/mL MC ranges) and superior to I (0.03-8 pg/mL MIC range) 
and A (0.5-4 pg/mL MIC range) for Aspegillus spp. The activities of 
the five agents were simdar for most of the emerging mold pathogens, 
but lower (0.01-4 pg/mL MIC ranges) than those for Aspetgillus spp. 
Conclusions: These in vitro data suggest the potential value of 
voriconazole and the other two new triazoles for the treatment of 
human mycoses caused by these molds. 
1 P751 1 Prevalence and antifungal susceptibility of 
vaginal Saccharomyces cerevisiae 
L. Pitzurra, M. Cesarini, M. Giammarioli, M. Giraldi, A. Sensini, 
M. Tristani, F. Bistoni. Microbiology Section, University o f  Perugia, 
.Peru&, Ztdy 
Objectives: To evaluate the prevalence and antifungal susceptibility 
of vaginal S. cerevisiae in women attending the Microbiology Unit of 
Perugia General Hospital. 
Methods: 1722 vaginal swabs were examined for genital tract 
yeast infection. Identification of S. cereuisiae was based on lack of 
germ-tube formation in human serum, absence of chlamydospore 
production, and results of carbohydrate assimilation profile tests. 
Susceptibilities to ainphotericin B, flucytosine, nystatin, miconazole, 
ketoconazole, econazole and fluconazole were evaluated by the 
NCCLS reference method. 
Results: In 381 (22%) patients, cultures were yeast positive. 
Candida albicans was the most frequently isolated species (73%) 
followed by S. cereuisiae (27%). Of patients positive for S. cereuisiae, 24 
were pregnant, 9 had a history of recurrent vulvovaginitis and vulvo- 
vaginal symptoms at sampling, and 5 had previously received multi- 
ple courses of antibiotics or fluconazole. All S. cereuisiae isolated 
showed a uniform degree of sensitivity to fluocytosine. Significant 
differences in susceptibility were observed with amphotericin B, 
nystatin and azoles. The highest degree of resistance was observed 
against ketoconazole and fluconazole. 
Conclusions: Vaginal colonization and symptomatic vaginitis due 
to S. cereuisiae, although rare, do occur. As S. cerevisiae isolates show 
variable resistance to azole antifungal agents, fungal cultures and anti- 
fungal susceptibility testing are valuable in confirming the diagnosis 
and selecting appropriate therapy. 
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Im1 Cytomegalovirus diagnosis in BMT patients- 
comparison of NASBA, PCR and antigen 
immunofluorescence assay 
A. Reip, H. Meisel. Institute of Virofon, C h a d ,  Medical Schooi o j  
Humboldt University, Berlin, Germany 
Objectives: Investigation of the applicability of the CMV pp67 
mRNA detection method for reliable diagnosis of an active CMV 
infection and for the monitoring of antiviral therapy in coniparison 
to other routinely established CMV detection methods. 
Methods: More than 100 blood samples of 20 bone marrow 
transplant (BMT) recipients were tested for CMV pp67 mRNA by 
NASBA (NucliSens, Organon Teknika), CMV DNA by PCR (in- 
house), and CMV pp65 antigen by immunofluorescence test 
(CinaKit, Argene/Biosoft). The observation periods lasted up to 8 
months post-BMT. 
Results: In 12 samples of three BMT patients CMV pp67 mRNA 
could be detected. Seven out of 12 mRNA-positive samples were 
CMV pp65 antigen positive as well. In all tested samples, detection 
of CMV mRNA correlated with the presence of CMV DNA by in- 
house PCR. All of the CMV mRNA-positive patients showed clin- 
ical symptoms of an active CMV infection. Under successful 
ganciclovir therapy, the loss of CMV mRNA was observed before 
the disappearance of pp65 antigen and CMV DNA. 
Conclusions: In close-meshed follow-up ofBMT patients, CMV 
pp67 mRNA assay is a reliable diagnostic tool for early diagnosis of 
CMV reactivation or infection. The preliminary data let us suggest 
that this marker should be beneficial for the prediction of CMV 
disease in BMT patients. CMV pp67 mRNA detection allows the 
timely start of pre-emptive ganciclovir therapy and earlier prediction 
of the efficacy of antiviral therapy than pp65 antigen or CMV-DNA. 
lp7531 The use of CMV pp65 antigenemia assay for 
diagnosis and treatment of cytomegalovirus 
infection in kidney recipients 
A.S. Pacsa, S. Tarek, R.K. Gupta, K.V. Johny, M.R.N. Nampoory. 
Faculty of Medicine, Kuwait University and Organ Eansplant Center, 
Ministry o f  Health, Kuwait 
Objectives: Evaluation of the CMV antigenemia assay for: (a) diag- 
nosing ongoing CMV infections and (b) monitoring the effective- 
ness of ganciclovir therapy. 
Methods: CMV pp65 antigen-positive leukocytes were deter- 
mined in serial samples of 82 kidney recipients ofwhom 23 received 
ganciclovir therapy. 
Results: Forty-five (55%) of the patients had the antigen in their 
leukocytes. Among these patients, there were 35 with CMV-related 
clinical symptoms. With a cut-off level of 5 antigen-positive cells/ 
50 000, the assay had a 93% positive and a 96% negative predictive 
value. After 2 weeks of ganciclovir treatment, antigen-positive leuko- 
cytes decreased considerably (< 5/50 000). or disappeared 
completely. Parallel with the decrease of pp65 antigen-positive cells, 
patients became free of CMV-related symptoms. 
Conclusions: The CMV antigenemia assay is useful for both 
diagnosing CMV disease and monitoring the effectiveness of antivi- 
ral therapy in kidney recipients. 
(p7541 The NucliSens CMV PP67 assay is a good 
predictor test for CMV disease occurrence in 
renal transplant recipients 
B.M. Imbert, C. Zandotti, V. FerrC, B. Vollant, J. Gattepaille, S .  
Billaudel. Virofon  Laboratory, Biology Institute, Nuntes University 
Hospital, Nantes, France 
Objectives: To evaluate the biological and clinical relevance of 
CMV mRNA detection in whole blood by the newly available 
NucliSens CMV pp67 assay. 
Methods: Twenty-five consecutive renal transplant recipients 
were prospectively followed during the first 120 postoperative days 
for CMV infection and disease. At each follow-up timepoint (once 
a week or twice a month), four assays were performed: viremia was 
determined by detection of early antigens in PBLs, DNAemia in 
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PMNLs was estimated by a home-made P C R  in the Us region, pp65 
aiitigenetnta was quantified using 1C3 MAb (Argkne Uiosoft) and late 
R N A  messengers of pp67 were detected using the NucliSens assay 
(Organon Teknika). The definition of an active infection was obser- 
vation of at least one positive result in viremia, or DNAemia or anti- 
geneiiiia. Data were then analyzed according to the occurrence of 
CMV disease-related symptoms (at least leukopenia and fever). 
Results: In total, 221 follow-up points were analyzed. Agreement 
between NucliSens and viremia, DNaemia and pp65 antigenemia 
was 8994, 88.5% and 89.2% repectively. Discrepancies were mostly 
observed in cases of low antigenemia levels (median 2 positive cells). 
A total of 12  patients developed active infections, 6 ofwhich involved 
CMV relapses. Eight episodes were related to CMV disease. When 
all active infection episodes were considered (n=18), PPV and NPV 
of the NucliSens assay were 1-espectively 0.75 and 0.95 for CMV 
disease diabmosis. When considering only the first active infection 
episode (ti=12), these values reached 0.89 and 1 respectively. 
Conclusions: The Nuclisens CMV pp67 assay is a helpful test to 
diagnose organ involvment during active CMV infection. 
(-1 Lung transplant: viral load evaluation in the 
monitoring of cytomegalovirus infections 
A. Gaeta, C. Nazzari, M. Antonelli, S. Quattrucci, T. Delli 
Castelli, C. Mancini. University of Rome, Rome, Italy 
Cytomegalovirus (HCMV) is one of the most serious viral compli- 
cations in lung transplant; the incidence may be as high as 80%. 
HCMV diagnosis and monitoring have been improved by the detec- 
tion of viral nucleic acid. Assuming that the viral genomic load is 
strictly related to the severity of infection, procedures able to quail- 
tify HCMV-DNA in peripheral blood are required to differentiate 
between replicative and latent infection. In the present report, 23 
lung transplant recipients were monitored for HCMV infection 
during 12 months from transplant. The study was carried out by anti- 
genemia test and quantitative evaluation of viral geiiomic load in 
polymorphonuclear cells (PMNLs) and the data were related to the 
clinical status of patients; during the follow-up, IgG and IgM to 
HCMV were also measured. Ebidence of HCMV infection appeared 
in 19 lung recipients and the first sign occurred between the 4th and 
the 10th week after transplantation. Clinical signs of HCMV were 
observed in 58% of infected patients, whereas 42% did not show any 
symptoms. The results obtained showed that viral DNA load rang- 
ing from 100 to 6000 genomic copies per 200 000 PMNLs corre- 
sponded to the presence of asymptomatic infection. Symptomatic 
infection was underlined by viral load more than 7000 genomic 
copies. With ;1 cut-off limit of 1000 genomic copies per 200 000 
PMNLs, sensitivity specificity and predictive values were higher in 
P C R  results than in antigenemia. Our findings indicate that the 
system described represents a useful approach in routinary diagnosis 
and thcrapeutic monitoring of lung transplant patients. 
lp7561 Fatal disseminated primary infection due to 
human herpesvirus-6 variant A in a renal 
transplant recipient 
C. Rossi, M.L. Delforge, F. Jacobs, M. Wising, 0. Pradier, B. Byl, 
11. Jacobovitz, J.P.Thys, C. Liesnard. Erasme University Hospital, 
Brussels, Be/@Lctn 
The human herpes-6 virus (HHV-6) includes A and B variants. 
Exantliema subititm and acute febrile illness in young children, bone 
marrow suppression, pneunionitis, hepatitis, encephalitis and skin 
rash in inimunowppressed patients have been attributed to HHV-6 
variant B. The spectrum of clinical manifestations due to HHV-6 A 
is still unknown. We describe the case of a 35-year-old kidney tran- 
plant recipient who developed a fatal primary HHV-6A infection. 
This paticnt with high immunosuppressive treatment due to prev- 
ous acute rejection developed a high fever, acute backbone pain, 
pancytopenia and hepatitis 19 days after transplantation (TX). A 
heniophagocytic syndrome accompanied by giant inmiimoblasts on 
bone niarmw biopsy and foci of hepatic necrosis with largo cells 
containing viral-like inclusions on liver biopsy was observed. The 
patient received ganciclovir, foscavir and hyperimmune globulins. 
Nevertheless, she became confused, with nieningismus and general- 
ized myoclonia. She developed respiratory failure requiring niechan- 
ical ventilation. She died 32 days after TX of fulniinant candideiina. 
HHV-6 A was detected by culture and P C R  on blood, bone marrow, 
CSF, bronchoalveolar lavage and liver biopsy. N o  other pathogen was 
found in these specimens. The HHV-6 iniiiiunohistocheniical stain- 
ing of bone marrow biopsy confirmed the presence of numerous cells 
expressing HHV-6 antigens. The patient, scronegative for HHV-6 
virus before grafting, developed both HHV-6 IgG and IgM 29 days 
after TX. The donor had antibodies against HHV-0. In conclusion, 
this patient developed, soon after TX, a fatal disteminated HHV-6 
variant A infection, probably transmitted by the graft. 
rp757j Parvovirus B I ~  infection in transplant 
recipients 
G. Callinella', S. Venturoli', E. Manaresi', G.L. Grazi2, M. 
Musiani', M. Zerbini'. Department 4 C h i d  and Expinzerrtal 
Mcdirirze, 'Department OJ Surgery and i'?atrsplar?tation, University .f 
~ ~ i ~ ~ ~ ~ ,  Italy 
Parvovirus B 19 infection can cause acute, generally self-limiting 
diseates in immunologically normal hosts: children and adults. In 
ininiunocoiiiproiiiised individuals, such as transplant recipients, B 1 9  
infection tends to become chronic, due to the impairment of the 
neutralizing antibody response. Several cases of U 19 infection have 
been described in solid organ and bone marrow transplant recipients, 
which mainly result in a symptomatic chronic red cell aplasia, due to 
the specific tropism of B 19 virus for red cell precursors. A prompt 
and accurate diagnosis can be useful since B 19 infection in immuno- 
compromised subjects can be successfully treated with inimunoglob- 
ulin administration. To evaluate the need for a routine screening of 
U 19 infection iu transplant recipients, we analyzed the incidence of 
the infection In a retrospective study performed on 329 serum 
saniplcs obtained from 257 transplant recipients. 
All the serum samples analyzed for U 19 DNA were obtained 
within 2 months from the transplantation. The diagnosis of active L1 
19 infection was performed by the detection of B 19 DNA in \erun~ 
samples with a PCR-ELISA assay. Out of the 329 serum wiiplet 
analyzed, 113 were from 95 bone marrow recipients, 27 from 26 
heart-transplanted individuals, 101 from 69 liver transplantations and 
88 from 67 renal transplant recipients. Three serum samples proved 
positive for B 19 DNA and were the only sample obtained from one 
bone marrow-transplanted patient and two liver transplant recipients 
respectively. Only o n e  liver transplant recipient had a B 19 sympto- 
matic infection with fever and anemia, which required blood trans- 
fusion. All three subjects with B 19 active infection proved to be IgM 
negative and IgG positive for specific B 1 9  structural antigen. Our 
conclusion is that the incidence of B 19 infection in transplant recip- 
ients does not require a routine screening, but B 1 0  DNA 5hould be 
investigated on the basis of clinical symptoms. 
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lp758] ESDL of HBV-infected renal transplant 
recipients is correlated with the accumulation 
of distinct virus mutants 
P. Preikschat’, P. Reinke’, A. Wagenerl, H.H. Neumayes, D.H. 
Kriiger’, H. Meisel’. ’Department of Virologx ’Department of 
Nephrolou, Campus Virchow Klinikum, jDepartment of Nephrologx 
Campus Mitte, HU, Berlin, Germany 
Objectives: In immunosuppressed (IS) renal transplant recipients 
chronic HBV infection often leads to end-stage liver disease (ESDL). 
Recently, we have demonstrated that the accumulation of HBV vari- 
ants with deletions in the central part of the C gene is correlated with 
severe liver disease. 
Methods: For a better understanding of the temporal and causal 
correlation between the selection of defined HBV genomes and liver 
pathogenesis, full-length HBV genomes from 38 long-term IS 
patients with chronic HBV infection were investigated by whole- 
genome and subsequent subgenomic PCR over a period of 2-7 years. 
Results: PCR fragments differing in size from wild-type frag- 
men6 could be detected for the C gene, core promoter/enhancer 11 
(Cp/EnhII) and preS 1/2 region, but never for the remaining P-gene 
regions and only in one case for the S gene. We showed that the 
correlated accumulation of variant virus populations carrying niuta- 
tions in the C gene and Cp/EnhII showed a significant fpO.043) 
association with ESDL. The mutants disappeared after cessation of IS 
and were preferentially eliminated under therapy with lamivudine. In 
addition, evolution of virus populations in relation to pathogenesis 
was analyzed by cloning and sequencing HBV full-length genomes 
from representative patients during a long-term follow-up. A specific 
pattern of mutant appearance and accumulation seems to be charac- 
teristic for patients developing ESDL. 
Conclusions: Thus, the molecular characterization of full-length 
HBV genomes constitutes a diagnostic and prognostic marker for the 
development of liver disease in these patients. 
A presumptive novel Nocardia species isolated 
from a lung transplant patient 
L. Maldonado, K. Isik, M. Goodfellow. Agriculture and 
Environmental Sciences, University of Newcastle, Newcastle, UK 
An actinomycete strain of the genus Nocardia was isolated from the 
bronchial lavage of a lung transplant patient. The strain was found to 
have properties consistent with its classification in the genus Nocardia. 
An almost complete gene sequence of the 16s rDNA of the strain 
was determined by sequencing the amplified gene. The sequence was 
then aligned with those available for nocardiae and phylogenetic trees 
inferred from these alignments. The organism clearly formed a 
distinct clade within the type strain of Nocardia asteroides. Up to now 
we have been distinguishing the strain from representatives of all 
validly described species of the genus Nocardia using a combination 
of phenotypic and genotypic properties. Our results show that the 
strain merits recognition as a new species of the genus Nocardia. 
However, further studies are required to unravel the relationships 
between Nocardia species which are difficult to identify a t  the species 
level such as the Nocardia asteroides complex. Finally, further studies 
may also reveal the importance of the genus Nocardia in human patho- 
genesis, as these organisms are usually misidentified by the clinical 
laboratory. 
Ip760) infectious complications in liver 
transplantation recipients at Vancouver 
Hospital 
A. Alothman’, M. Gribble’, S. Erb’, C. Scudamore’. ‘Department .f 
Medicine, King Fahad Hospital, Riyadh, Saudi Arabia; 2Hospital and 
Health Sciences Center, Vancouver, BC, Canada 
Objectives: To review the pre-transplant screening practices and 
determine the incidence of post- transplant infections at Vancouver 
Hospital. 
Methods: A retrospective chart review was conducted for patients 
who underwent orthotopic liver transplantation (OLT) procedures at 
Vancouver Hospital during the period between January and December 
1996. Follow-up was continued until July 1997. 
Results: Mean age of the 32 patients was 49 years, and 50% were 
males. 41% had hepatitis C infection and 20% had primary biliary 
cirrhosis as indications for transplantation. 25/32 (78%) were CMV 
+ve and all were negative for hepatitis B infection. 25/32 (78%) had 
TB-skin test done and 5 (20%) were positive. Among 33 OLT proce- 
dures, 31 (94%) were given selective bowel decontamination and 29 
(88%) were given IV ceftizoxime as perioperative prophylaxis. 32/33 
(97%) were given postoperative IV ganciclovir; 13 of those (41%) 
were CMV mismatch. 16 patients (50%) developed 18 postoperative 
bacterial infections (0.56 infectious episode per patient), 7 of which 
(39%) were caused by Enterococcus species. 2 patients (6%) developed 
CMV-reactivation dsease. 85% of the patients had an overall favor- 
able outcome. 
Conclusions: Compared to published data, the pre-transplant 
screening for infectious diseases in our center appears adequate, and 
the perioperative prophylaxis for bacterial infections seems effective. 
The postoperative IV ganciclovir needs to be standardized. 
[p7611 Prophylactic and pre-emptive strategies for 
control of legionnaires‘ disease in heart 
transplant recipients 
M. Hummel, M. Kurzuk, R. Hetzer. Deutsches Herzzentrum Berlin, 
Berlin, Germany 
Objectives: From 1987 until 1996, 1011 heart transplants (HTx) 
have been performed at our institute. Because the water supply 
system of the hospital is contaminated with Legionella spp. of up to 
100 colony-building units/mL, mostly of serogroup 1, which could 
not be cured by any technical means, HTx had to be performed in 
a high-risk environment. Therefore, prophylactic and pre-emptive 
strategies had to be developed to prevent legionnaires’ disease. 
Methods: To reduce the concentration of legionellae, water filter 
systems were installed in 1992 at all faucets. For screening of legion- 
ella infection, Legionella antigen in urine was determined at least once 
weekly by an ELISA kit in 742 out of 1011 pts (73%) from 1988 in 
addition to cultures of bronchial secretion, which were performed in 
any case of suspected infections from 1987. In cases of Legionella Ag 
detection, pre-emptive therapy with roxithromycin (1 50 mg b.i.d.) 
was instituted. 
Results: The mean annual incidence of legionella infection 
detected by urine-Ag was about 23% before water filter systems were 
installed. Thereafter it could only be reduced to a minimum of about 
15%. There was a 4-10-fold higher detection rate ofiegionella infec- 
tion by urine-Ag than by culture. Although infection rate could only 
be reduced to about 15% by use of water filter systems. pre-emptive 
therapy with roxithromycin in cases of Legionella Ag detection in 
urine could prevent legionnaires’ dsease nearly completely (annual 
incidence 1.9%). 
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sponding times, blood samples were also obtained for quantification 
7Sowmw(n=ll) 12,1/6,7 6,68/3,2 3,213.0 15,617,) 13,519,O 
Crr. freundit(n=IO) 9,3/6,8 58,8/8.3 8,5/3,6 61.2/ 11,s 14,4/6,9 of T. T concentration in tissues was quantified by HPLC/MS assay, 
and the tissue/serum ratio determined in individual subjects. T was AOspp.(n=lO) 7,1/3,6 4,9/3.1 5,3/3,1 14,9/3,9 19,0/4,1 P.~m@msa(fl=ll) 3,3/3,2 7.7513.6 4,75/3,1 5,4/3,2 4,013.2 
TRXalont CEFJmc AMIdooc miCEF TRX+AMI 
Conclusions: Even in a high-risk environment with a highly 
LeXiuriclla-contaminated water supply system, legionnaires' disease 
can be prevented efectively by use of (i) water filter systems, (ii) 
screening for Legionella Ag in urine and (iii) pre-emptive antibiotic 
therapy in cases of Lqionella Ag detection in urine. 
Pharmacokinetics/pharmacodynamics 
lp76211 Serum bactericidal activities (SBA) and 
pharmacokinetics (Pk) of trovafloxacin (TRX) 
alone and in combination with cefepime (CEF) 
or amikacin (AMI) in healthy volunteers 
B. Urodersen', S. Ziege', G. Schreiber', K. Borner', P. Koeppe', 
H. Lode'. 'Department of Chest/l&tiuus Diseases, City Hospital 
Heekeshorn, 'Benjamin-Franklin Hospital, Freie Universith't Berlin, 
Berlin, Germarzy 
Objectives and methods: The optimal combination partner for fluo- 
roquinolones which could expand the antimicrobial spectrum and 
improve antimicrobial activity due to synergistic interaction is not yet 
known. Therefore we investigated ex vivo the SBA and Pk of TFX 
alone and in Combination with CEF or AMI. 12 healthy volunteers 
(age: 25.15f2.6 years, mean 70.4214.4 kg) received over 1 h infu- 
sions of either 300 mg T K X  alone, 2000 mg CEF alone, 6 nig/kg 
AM1 alone or T R X  in Combination with CEF or AM1 at the same 
doses. SBAs were determined at 1, 10 and 24 h by a standardized 
microdilution method (NCCLS 1992) against 42 clinically isolated 
strains. Serum and urine concentrations of the three antibiotics were 
measured by HPLC or a fluorescence polarization immunoassay 
(AMI). 
Results: At the end of a 1-h infusion, the mean concentration of 
TFX alone was 4.63% 1.1 1 nig/L, and the concentrations of TFX in 
combination with AM1 or CEF were similar (4.72zk0.88/4.24? 
1 .16).The Pk parameters also showed no differences between single 
and combined administration ofTFX. The mean reciprocal titers for 
1 h /10 h 
and completely hydrolyzed to T in humans. Antibiotics must distrib- 
ute to the site of action in suficient concentration to be effective. 12 
subjects (age 37-70 years; weight 50-95.5 kg) received one dose of 
alatrofloxacin at a T equivalent dose of 200 mg 1-8 h prior to surgery. 
Colonic tissue, peritoneal fluid and blood samples were collected 
0.5-15 h after dosing for determination of T concentrations. The 
tissue/serum ratio for T was calculated for each subject. T distrib- 
uted rapidly into colonic tissue, achieving concentrations of 1.4 mg/g 
at 1.4 h, 2.8 mg/g at 2 h and 1.0 mg/g at 9.6 h after dosing. The 
mean T tissue/srrum ratio over the study duration was 0.74. In peri- 
toneal fluid, the maximum concentration of T (2 mg/L) was 
observed between 1.4 h and 2.2 h post-infusion. The mean peri- 
toneal Auid/serum concentration ratios at the times of incision, 
colonic tissue collection, and peritoneal closure, were 0.21, 0.43 and 
0.49. T was well tolerated by all subjects. The5e results indicate that 
one dose of T given prior to surgery rapidly distributes into colonic 
tissue, achieving concentrations similar to those in seruin 2-10 h 
post-infusion. In addition, T also distributes readily into peritoneal 
fluid. In both tissues, concentrations achieved are several times the 
MICw of several susceptible organisms. 
lp764/ Penetration of trovafloxacin into lung tissue, 
skeletal muscle, bone and skin in subjects 
undergoing thoracotomy 
K. Rolston', L. Dogolo', S. Willavize', J. Vincent'. 'M.D. 
Anderson Cancer Centev, Houston, T X ,  USA; 'P'zer Central Research, 
Groton, C?; USA 
Trovafloxacin (T) is a unique fluoroquinolone antibiotic with in vitro 
activity against atypical, Gram-negative, and Gram-positive respira- 
tory pathogens, including penicillin-resistant pneumococci, anaer- 
obes and kgionella species. Its long half-life and extensive tissue 
penetration permit once-daily dosing. Penetration of T into respira- 
tory tract and other tissues was evaluated in subjects undergoing 
thoracotomy. 11 subjects took T 200 nig o.d. for 3 days prior to 
surgery at predetermined times between 2 and 27 h after the last dose. 
Open biopsy specimens of lung tissue, skeletal muscle, bone, subcu- 
Conclusions: The combination of T R X  with CEF or AM1 was 
more active than the antimicrobial agents given alone. CEF was the 
more active combination partner for TRX;  however, activity against 
P aerryinosa was only nioderate with all single or combined antibi- 
otics. 
(p763j Colonic tissue and peritoneal fluid 
concentrations of trovafloxacin in patients 
undergoing colo-rectal surgery 
G. Melnik', W.H. Schwesinger , L.C. Dogolo', J. Vincent2. 
'The University 91 Exas Health Science Center, San Antonio, TX,  
USA; 'l'jizer Ccritral Researrh, Groto,i, C?; U S A  
Trovafloxacin (T) is a fluoronapthyridone related to well-known 
fluoroquinolone antibiotics. In contrast to other quinolones, T 
possesses activity against Enterobacteriaceae, Gram-positive organ- 
isms, including S. pneumoniae, and anaerobes, including B. jagi l is .  Its 
long terminal half-life suggests the feasibility of once-daily dosing. It 
i s  available in IV form as a prodrug (alatrofloxacin). which is readily 
the last dose were 2.1k1.2 mg/g in lungs, 1 .550.6 mg/g in skeletal 
muscle, 0.96k0.4 mg/g in bone, and 0.44k0.44 mg/g in skin, 
resulting in a tissue/serum ratio of 2.0 in lungs, 1.5 in skeletal muscle, 
1.0 in bone and skin and 0.4 in subcutaneous tissue. These results 
indicate that T achieves Concentrations several-fold higher than the 
MIC90 of the pathogens responsible for respiratory tract and other 
common infections in humans (e.g. S. prieumorriac 0.06-0.25 mg/L, 
H .  ir$uenzae 0.0084.03 mg/L, L. pneumophilia 0.008-0.06 mg/L, 
M. pneumoniae 0.25 mg/L, and S. aweus 0.03-0.12 nig/L. 
